Sinead Delany-Moretlwe

Sinead Delany-Moretlwe is a South African-born medical doctor, with post-graduate training in public health and clinical epidemiology. She has over fifteen years’ experience working in sexual and reproductive health and HIV prevention research, and has a particular interest in women’s health.

She has worked on several phase III trials of new HIV prevention technologies, and was an investigator on four different trials of herpes treatment for HIV prevention. She has also been an investigator on several phase II/III microbicides trials and is currently protocol chair of HPTN 084, a phase III trial of injectable cabotegravir for HIV prevention. She is an investigator on several oral PrEP studies in adolescent girls and young women that have documented high rates of asymptomatic curable STIs. Dr Delany-Moretlwe also has an interest in prevention and control of HPV infection and associated diseases and have worked on several longitudinal studies of HPV in people living with HIV to optimise prevention and control interventions for HPV.

She has worked closely with the South African Department of Health to support HPV vaccine introduction into South Africa, and led an evaluation of the first dose implementation in 2014. Dr Delany-Moretlwe has co-authored more than 100 publications and serves on several national and international advisory committees on PrEP and STI vaccines.